Brendan Kelley, M.D., Professor and Clinical Vice-Chair in the Department of Neurology at UT Southwestern Medical Center, sat down with KERA’s Sam Baker to discuss the test’s potential. Dr. Kelley leads UT Southwestern’s clinical trials on dementia, and points out that, while blood tests have been approved by the FDA and are far less invasive than other testing modalities, they may not be sufficient to establish an accurate diagnosis. Instead, a blood test may serve as a powerful screening tool to determine if further testing is warranted.